Health experts are alarmed as Republicans degrade the country’s pivotal HIV programs — and break promises made during Trump’s ...
Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...
Either we get ahead of this crisis or watch a generation of Americans be swept into the devastating grip of disease.
Celebrating the stories of PATF and Allies FEATURING: Kathi Boyle, Stuart Fisk, Tammy Frech, DJ Stemmler & Pam Vingle, Nachum Golan & Steve Hough, Alan Jones, ...
Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...
Jefferies London Healthcare Conference 2025 November 20, 2025 9:30 AM ESTCompany ParticipantsPeter Dannenbaum - Vice ...
Zacks Investment Research on MSN
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
Merck MRK announced positive top-line results from a pivotal late-stage study evaluating its investigational, once-daily, ...
The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...
Clinical Trials Arena on MSN
MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial
MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).
The initiative, funded by a $12 million grant from the National Institute on Drug Abuse, will evaluate how people with ...
Today, the image of what a family can look like has many possibilities, but the science that helps create families has not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback